Managers / Q2 2021 · view latest →
Rye Brook Capital LLC
CIK 0001844147 · 777 WEST PUTNAM AVE, SUITE 300, GREENWICH, CT, 06830 · 203-542-2822
Summary
Rye Brook Capital LLC reported $141M in U.S.-listed holdings across 27 positions for Q2 2021.
Its largest position, VEU, represents 14.5% of the portfolio.
Compared with Q1 2021, the fund opened 3 new positions and exited 5.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- ETP · 92.1% · $130M
- REIT · 7.5% · $11M
- Common Stock · 0.4% · $633,000
Quarter-over-Quarter Changes full breakdown →
vs Q1 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| SPYSPDR S&P 500 ETF TRUST | NEW | +54.0K | 54.0K | +$23M | $23M |
| TIPISHARES TIPS BOND ETF | NEW | +43.0K | 43.0K | +$6M | $6M |
| PFIXSIMPLIFY INTEREST RATE HEDGE | NEW | +25.4K | 25.4K | +$1M | $1M |
| TBTPROSHARES ULTRASHORT 20Y TR | ADDED | +94.0K | 124.8K | +$2M | $2M |
| VCRVANGUARD CONSUMER DISCRE ETF | SOLD OUT | −28.4K | 0 | −$8M | $0 |
| XBISPDR S&P BIOTECH ETF | SOLD OUT | −23.1K | 0 | −$3M | $0 |
| XLVHEALTH CARE SELECT SECTOR | SOLD OUT | −14.4K | 0 | −$2M | $0 |
| XHBSPDR S&P HOMEBUILDERS ETF | SOLD OUT | −23.7K | 0 | −$2M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2021
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $108M | 28 | Apr 29, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $107M | 27 | Jan 27, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $192M | 31 | Oct 21, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $96M | 24 | Jul 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $80M | 20 | Apr 16, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $83M | 29 | Feb 3, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $69M | 19 | Oct 22, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $76M | 25 | Jul 22, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $171M | 28 | Apr 11, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $196M | 30 | Jan 30, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $141M | 28 | Oct 10, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $212M | 26 | Jul 24, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $164M | 27 | Apr 21, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $154M | 23 | Jan 6, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $137M | 21 | Nov 3, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $164M | 22 | Jul 21, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $253M | 32 | Apr 28, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $390M | 29 | Jan 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $142M | 27 | Oct 4, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $141M | 27 | Jul 19, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $137M | 28 | Apr 9, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $115M | 24 | Feb 3, 2021 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.